Skip to main content
. Author manuscript; available in PMC: 2018 Feb 10.
Published in final edited form as: Nature. 2017 Aug 2;548(7666):234–238. doi: 10.1038/nature23291

Figure 4. Class 3 BRAF-mutant tumours with wild-type RAS/NF1 are sensitive to inhibition of RTK-dependent RAS activation.

Figure 4

a, A patient with metastatic colorectal cancer (BRAF(G466V)) involving the liver was treated with panitumumab plus irinotecan. Their liver lesions (marked with arrows on CT scan) were compared before or after 4 months of drug treatment. b, c, PDX was established from a tumour biopsy specimen from the patient indicated in a. Drug response was monitored by measurement of the tumour sizes. Vemurafenib was given at 75 mg kg−1 twice per day, trametinib 1.5 mg kg−1 once daily. Cetuximab (50 mg kg−1) was given twice per week. Data in graphs are mean ± s.d., n =10. d, PDX was established from the progressing ovarian metastasis from a CDC patient. INC280 was given at 10 mg kg−1 twice per day, trametinib 1.5 mg kg−1 once daily. Data in graphs are mean ±s.d., n = 5. P value calculated by unpaired t-test.